{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:14:29Z","timestamp":1792178069833,"version":"4.4.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1097\/jcp.0b013e3182905d6a","type":"journal-article","created":{"date-parts":[[2013,6,15]],"date-time":"2013-06-15T11:05:57Z","timestamp":1371294357000},"page":"520-524","source":"Crossref","is-referenced-by-count":29,"title":["Effects of Controlled Discontinuation of Long-Term Used Antipsychotics on Weight and Metabolic Parameters in Individuals With Intellectual Disability"],"prefix":"10.1097","volume":"33","author":[{"given":"Gerda","family":"de Kuijper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen","family":"Evenhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter J.","family":"Hoekstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210128","first-page":"1083","article-title":"Drug use by mentally handicapped persons in institutions and family-replacing residential facilities.","volume":"139","author":"van Schrojenstein Lantman-de Valk","year":"1995","journal-title":"Ned Tijdschr Geneeskd"},{"key":"R2-11-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-2002-19838","article-title":"Psychotropic drug use in intellectually disabled group-home residents with behavioural problems.","volume":"35","author":"Stolker","year":"2002","journal-title":"Pharmacopsychiatry"},{"key":"R3-11-20210128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00228-005-0935-4","article-title":"Drug utilisation by children and adolescents with mental retardation: a population study.","volume":"61","author":"Tobi","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"R4-11-20210128","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2788.2010.01275.x","article-title":"Use of antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: prevalence and reasons for prescription.","volume":"54","author":"de Kuijper","year":"2010","journal-title":"J Intellect Disabil Res"},{"key":"R5-11-20210128","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2165\/11530020-000000000-00000","article-title":"Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.","volume":"23","author":"Bhuvaneswar","year":"2009","journal-title":"CNS Drugs"},{"issue":"suppl 1","key":"R6-11-20210128","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.","volume":"68","author":"Newcomer","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R7-11-20210128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatmentpharmacological mechanisms.","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacol Ther"},{"key":"R8-11-20210128","first-page":"1","article-title":"The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain Prog Neuropsychopharmacol Biol Psychiatry.","volume":"34","author":"Deng","year":"2010","journal-title":""},{"key":"R9-11-20210128","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.4088\/JCP.v66n0912","article-title":"Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.","volume":"66","author":"McKee","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R10-11-20210128","doi-asserted-by":"crossref","first-page":"405","DOI":"10.31887\/DCNS.2009.11.4\/tlencz","article-title":"Pharmacogenetics of antipsychotic-induced side effects.","volume":"11","author":"Lencz","year":"2009","journal-title":"Dialogues Clin Neurosci"},{"key":"R11-11-20210128","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.pnpbp.2005.03.019","article-title":"The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment.","volume":"29","author":"Reynolds","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R12-11-20210128","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.pnpbp.2006.12.021","article-title":"759 CT polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment.","volume":"31","author":"Ryu","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R13-11-20210128","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/JCP.0b013e3180a76dc0","article-title":"The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia.","volume":"27","author":"Mulder","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R14-11-20210128","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/sj.tpj.6500422","article-title":"The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study.","volume":"7","author":"Mulder","year":"2007","journal-title":"Pharmacogenomics J"},{"key":"R15-11-20210128","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2010.11.030","article-title":"Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics.","volume":"125","author":"Bai","year":"2011","journal-title":"Schizophr Res"},{"key":"R16-11-20210128","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1089\/cap.2009.0071","article-title":"Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene.","volume":"20","author":"Hoekstra","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R17-11-20210128","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2217\/pgs.11.67","article-title":"Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review.","volume":"12","author":"Risselada","year":"2011","journal-title":"Pharmacogenomics"},{"key":"R18-11-20210128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4088\/JCP.v62n0405","article-title":"A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities.","volume":"62","author":"Buitelaar","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R19-11-20210128","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1365-2788.2007.00950.x","article-title":"The effectiveness of antipsychotic medication in the management of behaviour problems in adults with intellectual disabilities.","volume":"51","author":"Deb","year":"2007","journal-title":"J Intellect Disabil Res"},{"key":"R20-11-20210128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(08)60072-0","article-title":"Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial.","volume":"371","author":"Tyrer","year":"2008","journal-title":"Lancet"},{"key":"R21-11-20210128","first-page":"CD000377","article-title":"Antipsychotic medication for challenging behaviour in people with learning disability.","volume":"3","author":"Brylewski","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"R22-11-20210128","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1365-2788.2010.01353.x","article-title":"Representation of people with intellectual disabilities in randomised controlled trials on antipsychotic treatment for behavioural problems.","volume":"55","author":"Scheifes","year":"2011","journal-title":"J Intellect Disabil Res"},{"key":"R24-11-20210128","first-page":"657","article-title":"Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses J Clin Psychopharmacol.","volume":"23","author":"Rijcken","year":"2003","journal-title":""},{"key":"R25-11-20210128","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/000992280404300504","article-title":"Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders.","volume":"43","author":"Lindsay","year":"2004","journal-title":"Clin Pediatr (Phila)"},{"key":"R26-11-20210128","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/schbul\/sbl037","article-title":"A case series: evaluation of the metabolic safety of aripiprazole.","volume":"33","author":"De Hert","year":"2007","journal-title":"Schizophr Bull"},{"key":"R27-11-20210128","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","article-title":"A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).","volume":"168","author":"Stroup","year":"2011","journal-title":"Am J Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e3182905d6a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:01:35Z","timestamp":1620957695000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201308000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3182905d6a","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}